Laboratory Filtration - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The laboratory filtration market size is estimated at USD 5.01 billion in 2026, and is expected to reach USD 7.58 billion by 2031, at a CAGR of 8.63% during the forecast period (2026-2031). This report is Segmented by Product Type (Filtration Media, Filtration Assemblies, Filtration Accessories), Technique (Microfiltration, Ultrafiltration, and More), End User (Pharmaceutical & Biotechnology Companies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Laboratory Filtration Market Trends and Insights

Accelerating Biopharma R&D Spend

Global pharmaceutical R&D reached USD 244 billion in 2025, a 7.5% increase year-over-year, with biologics accounting for 62% of this expenditure. Each investigational new drug submission now triggers 15-20 sterility and viral clearance validation runs, which translates into a membrane area equivalent to three to five production batches. Contract laboratories experienced a 28% increase in sample throughput for stability testing, prompting procurement managers to negotiate long-term filtration-media agreements that secure price and availability. Regulators continue to refine guidance on process validation, prompting sponsors to repeat studies to meet evolving sterility benchmarks, thereby sustaining membrane consumption. The upshot is a durable baseline of recurring orders that helps the laboratory filtration market weather macroeconomic swings.

Expansion of Cell & Gene Therapy Manufacturing

Approved cell- and gene-therapy products climbed to 37 by end-2025, and 180 programs advanced to Phase II/III, doubling the installed base of GMP suites dedicated to viral-vector work. Lentiviral and AAV purification depend on tangential-flow filtration, with each 50-L bioreactor run consuming around 12 m² of hollow-fiber membrane. Sartorius reported that cell-therapy customers rose from 11% to 19% of its bioprocess revenue between 2023 and 2025, underlining how the segment reshapes order books. Commercial-scale expansion will require a tenfold increase in filtration capacity by 2028, compelling CDMOs to pre-qualify multiple suppliers. Vendors able to furnish viral-retention data across diverse serotypes enjoy a widening moat in the laboratory filtration market.

Supply-Chain Volatility for High-Grade Membrane Polymers

Polyvinylidene fluoride and polyethersulfone resins originate from just three Asian producers, so any disruption cascades through lead times of 8 to 12 weeks for finished rolls. A typhoon shut down a Taiwan PVDF plant in August 2025, reducing availability by 18% and driving up spot prices for pharmaceutical-grade PES by 23%. Large vendors hedge with multi-year offtake contracts, but mid-tier assemblers endure allocation cuts that erode margins. Regulatory dossiers name specific membrane chemistries, making emergency substitutions costly. Vertical integration, such as Sartorius’ 2024 acquisition of a PES compounder, partially insulates top players; however, supply shocks remain a structural headwind for the laboratory filtration market.

Other drivers and restraints analyzed in the detailed report include:

• Rapid Adoption of Single-Use Filtration Assemblies
• Miniaturized High-Throughput Screening Driving Microfiltration Demand
• Waste-Disposal Compliance Costs for Single-Use Plastics

Segment Analysis

Filtration Media captured 57.31% of revenue in 2025, underscoring the centrality of membrane rolls, pleated cartridges, and capsule filters to every stage of bioprocessing. Commoditization of 0.22-µm discs compresses margins, so suppliers differentiate through hydrophilic coatings and charged layers that command 20% premiums. Filtration Accessories, though smaller in value, are forecast to expand at a 10.92% CAGR to 2031 as laboratories automate liquid handling. A single screening robot can process 10,000 syringe filters per day, making accessories the fastest-growing segment of the laboratory filtration market.

Media stays on top because each biologics batch consumes square meters of membrane, but accessories now drive incremental profit. Bundling precision filters with pipetting decks locks in aftermarket revenue and discourages third-party alternatives. Filtration Assemblies, which include plug-and-play capsules and tangential-flow skids, sit between the two extremes, winning favor at CDMOs that prioritize rapid tech transfer over bespoke engineering. The laboratory filtration market size for assemblies is poised to increase in line with the uptake of single-use products; however, its growth rate lags behind the accessory boom due to longer unit replacement cycles.

Complete Report Scope:

• By Product Type
  • Filtration Media
  • Filtration Assemblies
  • Filtration Accessories
• By Technique
  • Microfiltration
  • Ultrafiltration
  • Nanofiltration & Reverse Osmosis
  • Vacuum / Depth Filtration
  • Others
• By End User
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Food & Beverage Testing Laboratories
  • Environmental Testing Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 36.24% revenue in 2025, backed by more than 1,200 GMP suites and the world’s densest cluster of cell-therapy developers. U.S. CDMOs trial next-generation membranes first, so suppliers channel pilot lots to local customers, reinforcing the region’s status as an early adopter. Canada’s vaccine initiative funnels grants into single-use, ready-to-pilot plants, expanding the pull of accessories.

The Asia-Pacific region is the growth engine, with an 11.63% CAGR projected through 2031. China licensed 47 biosimilar plants in 2024, and India approved 29 biologics facilities in 2025 that standardized on disposable trains to satisfy U.S. FDA export norms. Samsung Biologics and WuXi Biologics added over 400,000 L of capacity, selecting partners who can deliver within 48 hours. Japan retrofits stainless steel lines with hybrid single-use modules to reduce cleaning and validation downtime, spurring demand for capsule filters.

Europe expands steadily, driven by EMA guidance on continuous manufacturing, which heightens the need for inline filtration. Germany and Switzerland are pivoting to autologous CAR-T platforms, so each patient lot requires dedicated filters, which lifts per-lot spend by up to 50%. The United Kingdom’s post-Brexit convergence with EU standards eases supplier compliance. The Middle East & Africa are smaller today, yet Gulf states pledged USD 1 billion in 2025 for local biopharma, importing filtration assemblies until regional conversion plants emerge. South America’s Brazil and Argentina push vaccine self-reliance; Fiocruz opened a 50,000-L complex in 2025 fitted with tangential-flow disposables. Across all regions, greenfield facilities leapfrog to single-use, accelerating the adoption of premium capsules and assemblies in the laboratory filtration market.

List of Companies Covered in this Report:

• 3M
• Agilent Technologies
• Avantor Inc. (VWR)
• Clarcor Industrial Air
• Cobetter Filtration Group
• Cole-Parmer (Antylia Scientific)
• Corning
• Danaher Corp. (Cytiva & Pall)
• Donaldson Company Inc.
• Eaton
• GVS
• Membrane Solutions LLC
• Merck KGaA (MilliporeSigma)
• Parker Hannifin
• Porvair plc
• Repligen
• Sartorius
• Sterlitech
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support